The WACC of Korea Arlico Pharm Co Ltd (260660.KQ) is 6.8%.
| Range | Selected | |
| Cost of equity | 6.10% - 8.00% | 7.05% |
| Tax rate | 12.00% - 12.50% | 12.25% |
| Cost of debt | 5.90% - 7.00% | 6.45% |
| WACC | 5.9% - 7.6% | 6.8% |
| Category | Low | High |
| Long-term bond rate | 3.1% | 3.6% |
| Equity market risk premium | 5.8% | 6.8% |
| Adjusted beta | 0.52 | 0.58 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 6.10% | 8.00% |
| Tax rate | 12.00% | 12.50% |
| Debt/Equity ratio | 0.27 | 0.27 |
| Cost of debt | 5.90% | 7.00% |
| After-tax WACC | 5.9% | 7.6% |
| Selected WACC | 6.8% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for 260660.KQ:
cost_of_equity (7.05%) = risk_free_rate (3.35%) + equity_risk_premium (6.30%) * adjusted_beta (0.52) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.